Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement

C. A. M. Bouman*, N. van Herwaarden, F. H. J. van den Hoogen, A. van der Maas, B. J. F. van den Bemt, A. A. den Broeder

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)597-603
Number of pages7
JournalExpert Opinion on Drug Metabolism & Toxicology
Volume13
Issue number6
DOIs
Publication statusPublished - 2017

Keywords

  • Antibodies
  • rheumatoid arthritis
  • tapering
  • therapeutic drug monitoring
  • tumor necrosis factor inhibitor
  • DISEASE-ACTIVITY
  • ANKYLOSING-SPONDYLITIS
  • CLINICAL-RESPONSE
  • FOLLOW-UP
  • DOUBLE-BLIND
  • EFFICACY
  • ASSOCIATION
  • COHORT
  • GOLIMUMAB
  • SAFETY

Cite this